Skip to content
NYSE · OPHTHALMIC GOODS · LARGE CAP

Alcon Inc. ALC

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$10.3B
▲ 4.9% YoY
$980.0M
▼ 3.7% YoY
$1.7B
▲ 7.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Alcon researches, develops, manufactures, distributes and sells eye care products. It employs over 25,000 associates operating in 56 countries and serves consumers and patients in over 140 countries and territories. It is organized into two global business segments: Surgical and Vision Care. Its Surgical segment offers implantable products, consumables and equipment for use in surgical procedures addressing cataracts, vitreoretinal conditions, refractive errors and glaucoma, with a portfolio that includes equipment, instrumentation and diagnostics, IOLs and other implantables, and a broad line of consumables including viscoelastics, surgical solutions, incisional instruments and surgical custom packs. Its Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, cell therapies to treat ocular diseases and a comprehensive portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma and contact lens care, as well as ocular vitamins and redness relievers. For the year ended December 31, 2025, its Surgical business had approximately $5.8 billion in net sales of implantables, consumables and equipment, as well as services and other surgical products, and its Vision Care business had approximately $4.6 billion in net sales of contact lens and ocular health products.

Written from the business description in ALCON INC's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 10.3B
Revenue, FY2025 · full 9-year series below
Revenue $B Net income $B
FY2025 · Revenue 10.3 · Net income 1.0
5B10B
2017202020232025
Compound annual growth
+6.0%
+8.8%
+42.8%
+103.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.8% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

9 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 13.2% · Net 9.5%
5%10%-5%
201720212025
ROE
FY2025 · ROE 4.5%
2%4%-1%-2%-3%
201720212025
Three returns, three denominators.

Each USD of equity produced 4 cents of profit this year.

Cash & shareholders

USD 842.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.7
1B2B
201720212025
Net buybacks $M Dividends $M
FY2025 · Dividends 166.0 · Net buybacks 676.0
300M600MDividendsNet buybacks
2019202020212022202320242025

USD 166.0M in dividends and USD 676.0M in buybacks — 86% of the year's profit went back to shareholders.

Total assetsUSD 31.6B
EquityUSD 22.0B
CashUSD 1.5B
Gross debtUSD 4.7B
Net debtUSD 3.2B
Current ratio2.12×

Net debt stands at 15% of equity.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ALC, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B10.39.89.48.78.26.87.47.26.8
Operating income $B1.41.41.00.70.6−0.5−0.2−0.2−0.1
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B0.20.2−0.10.10.0−0.10.3−0.1−0.4
Net income $B1.01.01.00.30.4−0.5−0.7−0.20.3
Free cash flow $B1.71.60.70.60.60.30.40.60.8
EPS, diluted $1.982.051.960.680.76−1.09−1.34−0.460.52
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout %1713123014−0−0——
ROE %4.54.84.81.72.0−2.8−3.1−1.01.1
Shares out B◌◌◌◌◌0.490.49◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 43 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityOphthalmic Goods
Listed onNYSE
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image